Related Experiment Video
Updated: May 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO?
Earle F Burgess1, Derek Raghavan
1Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, USA. earle.burgess@carolinashealthcare.org
Abstract:
In recent years, management of prostate cancer has benefited from an expanding array of new pharmacological options that are the result, in part, of an increased understanding of, and ability to target, androgen signaling. Further characterization of additional molecular pathways relevant to prostate cancer tumorigenesis has identified new molecular targets in prostate cancer that may be amenable to therapeutic intervention with novel agents. In addition, novel radioisotope therapies and cytotoxic agents have shown significant anticancer efficacy with manageable patterns of toxicity, and will eventually have to be integrated into our algorithms of therapy. This review summarizes recent findings in clinical prostate cancer research reported at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology (ASCO) and addresses their relevance to clinical practice.
Insights
Recent advances in prostate cancer treatment include new drugs targeting androgen signaling and novel therapies like radioisotopes. These findings from the 2012 American Society of Clinical Oncology meeting offer improved clinical options.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostate cancer management is evolving with new pharmacological options.
- Increased understanding of androgen signaling pathways aids targeted therapies.
Framework:
- New molecular targets in prostate cancer tumorigenesis are being identified.
- Novel agents are being developed for therapeutic intervention.
Implementation:
- Novel radioisotope therapies and cytotoxic agents demonstrate significant anticancer efficacy.
- These therapies show manageable toxicity patterns.
Implications:
- Findings from the 2012 American Society of Clinical Oncology (ASCO) meeting offer insights into clinical practice.
- Integration of novel therapies into treatment algorithms is necessary.
Related Concept Videos
Cancer Survival Analysis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistent Cancers
Cancer Prevention
Some...
Cancer Prevention
Some...

